Michael Fiore's departure as Chief Commercial Officer of Healthequity, Inc. was reported, effective October 5, 2026; the filing names no successor. As of November 6, 2026, Healthequity, Inc. has reported 4 leadership change filings to the SEC under Item 5.02 of Form 8-K, from March 30, 2026 to October 9, 2026, naming 2 departures (Form 8-K, October 9, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Healthequity, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: Out · Person: Michael Fiore · Role: Chief Commercial Officer · Effective: 2026-10-05 · 8-K, 2026-10-09
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-09-30
- · In / out: Out · Person: Eli Rosner · Role: Chief Technology Officer · Effective: 2026-04-17 · 8-K, 2026-04-06
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-03-30
Healthequity, Inc. reported changes in 4 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-03-30 to 2026-10-09. They name 2 people. Every row below is cited to the filing it comes from, and this page adds each new change as Healthequity, Inc. files it.
Also on the record for Healthequity, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 9, 2026 | Stake report, Schedule 13G/A, by Wasatch Advisors LP | 8.5% of the class | 5%+ stakes | Source |
| July 31, 2026 | Stake report, Schedule 13G/A, by Vanguard Portfolio Management | 4.94% of the class | 5%+ stakes | Source |
| July 15, 2026 | Stake report, Schedule 13G/A, by Wasatch Advisors LP | 9.5% of the class | 5%+ stakes | Source |
| April 30, 2026 | Stake report, Schedule 13G, by Vanguard Capital Management | 5.3% of the class | 5%+ stakes | Source |
| April 29, 2026 | Stake report, Schedule 13G, by Vanguard Portfolio Management | 5.01% of the class | 5%+ stakes | Source |
| March 27, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| November 5, 2025 | Stake report, Schedule 13G/A, by FMR LLC | 4.1% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Healthequity, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Healthequity, Inc. and the records around it.
Healthequity, Inc. elsewhere on the record
Companies that share a holder
- Wasatch Advisors LP also filed stake reports on 72 other companies: Smith Douglas Homes Corp (Oct 2026), Amtech Systems Inc (Oct 2026), BBB Foods Inc (Oct 2026)
- FMR LLC also filed stake reports on 761 other companies: ASPEN NEUROSCIENCE INC (Nov 2026), AVALO THERAPEUTICS INC (Nov 2026), BRAZE INC (Nov 2026)
- Vanguard Portfolio Management also filed stake reports on 941 other companies: Newmark Group Inc (Nov 2026), A10 Networks Inc (Oct 2026), ADT Inc (Oct 2026)
Watch Healthequity, Inc.
Get an email when Healthequity, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Healthequity, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Healthequity, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Healthequity, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
11 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-10-09 | Out | Chief Commercial Officer | 2026-10-05 | 8-K, 2026-10-09 | |
| 2026-09-30 | Reported | not named in the filing | 8-K, 2026-09-30 | ||
| 2026-04-06 | Out | Chief Technology Officer | 2026-04-17 | 8-K, 2026-04-06 | |
| 2026-03-30 | Reported | not named in the filing | 8-K, 2026-03-30 |
Who leads Healthequity, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Commercial Officer: Michael Fiore, departure reported, effective 2026-10-05 (filed 2026-10-09). No successor is named in these filings.
- Chief Technology Officer: Eli Rosner, departure reported, effective 2026-04-17 (filed 2026-04-06). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on Healthequity, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Commercial Officer at Healthequity, Inc., with the record behind each one.
Find candidates like Chief Commercial Officer at Healthequity, Inc.Every change, in the filing's words
Departing: Michael Fiore, Chief Commercial Officer, effective 2026-10-05
The employment of Michael Fiore, the Chief Commercial Officer at HealthEquity, Inc. (the "Company"), was terminated by the Company without cause, effective October 5, 2026.
- The responsibilities of the Chief Commercial Officer will be redistributed to other members of the Company's management team.
Reported
On September 24, 2026, the Board of Directors (the "Board") of HealthEquity, Inc. (the "Company") appointed No mie Heuland as a member of the Board, effective immediately.
- In connection with Ms. Heuland's appointment to the Board, the Board expanded the size of the Board to eleven members from its current ten members.
- Ms. Heuland will serve on the Audit and Risk Committee and Cybersecurity and Technology Committee of the Board.
- Ms. Heuland is the Chief Financial Officer of Moody's Corporation ("Moody's").
- During the fiscal year ended January 31, 2026, the Company paid approximately $146,519 to Moody's controlled subsidiaries for (1) ratings services for the Company's outstanding bonds, and (2) data sets used for internal modeling.
- The Company expects to pay Moody's controlled subsidiaries an amount that exceeds $120,000 in the fiscal year ending January 31, 2027.
- Ms. Heuland will receive the standard director compensation that the Company provides to its non-employee directors pursuant to the Company's Non-Employee Director Compensation Policy (the "Policy").
- Ms. Heuland will receive retainer fees and additional annual equity awards in accordance with the terms and conditions of the Policy, the form of which has been previously filed with the Securities and Exchange Commission (the "SEC").
- Ms. Heuland will also enter into the Company's standard form of indemnification agreement, the form of which has been previously filed with the SEC.
Departing: Eli Rosner, Chief Technology Officer, effective 2026-04-17
On April 6, 2026, HealthEquity, Inc. (the "Company") announced that the employment of Eli Rosner, the Company's Chief Technology Officer, will be terminated by the Company without cause, effective April 17, 2026.
- Sunil Rajasekar, the Company's Executive Vice President, Chief Product and Strategy Officer, will be responsible for overseeing the Company's technology organization as of that date.
- Sunil Rajasekar has served as the Company's Executive Vice President, Chief Product and Strategy Officer since January 2026.
- Prior to joining HealthEquity, Mr. Rajasekar was the Chief Executive Officer and a director at BTRS Holdings, Inc., d/b/a Billtrust, from November 2022 through August 2025.
- Prior to serving as Billtrust's Chief Executive Officer, Mr. Rajasekar served as the President of MINDBODY, Inc. from September 2018 through August 2022.
- He was a General Manager at eBay Inc. from May 2016 through July 2018, the Chief Technology and Product Officer at Lithium Technologies, Inc. (currently d/b/a Khoros, LLC) and a Vice President at Intuit Inc. from February 2004 to May 2012.
- Prior to joining Intuit, Mr. Rajasekar held various senior roles at Cisco Corporation and Oracle Corporation.
- Mr. Rajasekar holds a Bachelor of Commerce from Loyola University and an M.B.A. from the University of Toledo.
Reported
On March 26, 2026, the Board of Directors (the "Board") of HealthEquity, Inc. (the "Company") announced the appointment of William Gassen as a member of the Board, effective immediately.
- In connection with Mr. Gassen's appointment to the Board, the Board expanded the size of the Board to ten members from its current nine members.
- Mr. Gassen will serve on the Audit and Risk Committee and Talent, Compensation and Culture Committee (the "TCCC") of the Board.
- Mr. Gassen is the Chief Executive Officer of Sanford Health.
- During the fiscal year ended January 31, 2026, the Company received revenues of $123,923 from Sanford Health for providing consumer-directed benefits to its employees and expects to receive revenue from Sanford Health in the fiscal year ending January 31, 2027, in an amount that exceeds $120,000.
- Mr. Gassen will receive the standard director compensation that the Company provides to its non-employee directors pursuant to the Company's Non-Employee Director Compensation Policy (the "Policy").
- Mr. Gassen will receive retainer fees and additional annual equity awards in accordance with the terms and conditions of the Policy, the form of which has been previously filed with the Securities and Exchange Commission (the "SEC").
- Mr. Gassen will also enter into the Company's standard form of indemnification agreement, the form of which has been previously filed with the SEC.
Tools for this story
Each opens in a new tab, filled in for Healthequity, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.